Meeting
2023 ASCO Annual Meeting
Immunotherapy for localized dMMR/MSI tumors: First interim analysis of the IMHOTEP trial.
Authors
Christelle De La Fouchardiere
Medical Oncology Department, Centre Leon Berard, Lyon I University, Lyon, France
Christelle De La Fouchardiere , Aziz Zaanan , Romain Cohen , Samuel Le Sourd , David Tougeron , Emilie Soularue , Olivier Dubreuil , Nicolas Willet , Emmanuelle Samalin , Guillaume Piessen , Vincent Hautefeuille , Marine Jary , Meher Ben Abdelghani , Ludovic Evesque , Philippe Rochigneux , Ellen Blanc , Aymeric De Montfort , Frédéric Bibeau , Clélia Coutzac
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Clinical Trial Registration Number
NCT04795661
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2591)
DOI
10.1200/JCO.2023.41.16_suppl.2591
Abstract #
2591
Poster Bd #
433
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Immunotherapy for localized MSI-H colorectal cancer: Characterizing endoscopic and imaging response.
First Author: Daniel Aaron Fox
Poster
2017 ASCO Annual Meeting
Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.
First Author: Peter Schmid
Poster
2024 ASCO Annual Meeting
Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.
First Author: Naixin Ding
Poster
2024 ASCO Annual Meeting
19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.
First Author: Kristoffer Staal Rohrberg